β1-Adrenergic blocker; nitric oxide-mediated vasodilator. Prepd as racemic mixture of (R,S,S,S)- and (S,R,R,R)-enantiomers. Prepn: G. R. E. Van Lommen et al., EP 145067; eidem, US 4654362 (1985, 1987 both to Janssen); eidem, J. Pharm. Belg. 45, 355 (1990). HPLC fluorescence determn in plasma: R. Woestenborghs et al., Methodol. Surv. Biochem. Anal. 18, 215 (1988). Receptor binding study: P. J. Pauwels et al., Mol. Pharmacol. 34, 843 (1988). Clinical study of vasodilating effects: J. R. Cockcroft et al., J. Pharmacol. Exp. Ther. 274, 1067 (1995). Clinical trial in hypertension: T. J. Cleophas et al., Clin. Ther. Res. 62, 451 (2001); in endothelial dysfunction with hypertension: N. Tzemos et al., Circulation 104, 511 (2001). Review of pharmacology: M. Mangrella et al., Pharmacol. Res. 38, 419-431 (1998); of clinical development: J. Cockcroft, Expert Opin. Pharmacother. 5, 893-899 (2004).
Antihypertensive.
β-Adrenergic Blocker; Antihypertensive; Aryloxypropanolamine Derivatives; Vasodilator (Peripheral)